Personalis Management

Management criteria checks 1/4

Personalis' CEO is Chris Hall, appointed in Dec 2022, has a tenure of 1.75 years. total yearly compensation is $1.73M, comprised of 30.9% salary and 69.1% bonuses, including company stock and options. directly owns 0.25% of the company’s shares, worth €981.46K. The average tenure of the management team and the board of directors is 3.3 years and 2.5 years respectively.

Key information

Chris Hall

Chief executive officer

US$1.7m

Total compensation

CEO salary percentage30.9%
CEO tenure2yrs
CEO ownership0.3%
Management average tenure3.3yrs
Board average tenure2.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Chris Hall's remuneration changed compared to Personalis's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$91m

Jun 30 2024n/an/a

-US$81m

Mar 31 2024n/an/a

-US$93m

Dec 31 2023US$2mUS$534k

-US$108m

Sep 30 2023n/an/a

-US$113m

Jun 30 2023n/an/a

-US$110m

Mar 31 2023n/an/a

-US$114m

Dec 31 2022US$2mUS$83k

-US$113m

Compensation vs Market: Chris's total compensation ($USD1.73M) is above average for companies of similar size in the German market ($USD1.02M).

Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.


CEO

Chris Hall (55 yo)

2yrs

Tenure

US$1,726,790

Compensation

Mr. Christopher M. Hall, also known as Chris, served as Senior Vice President and Head of Diagnostics Business at Personalis, Inc. since October 2022 until December 31, 2022 and serves as its President sin...


Leadership Team

NamePositionTenureCompensationOwnership
Christopher Hall
President2yrsUS$1.73m0.25%
€ 981.5k
Aaron Tachibana
CFO & COO5.8yrsUS$1.67m0.23%
€ 893.3k
Stephen Moore
Senior VP & Chief Legal Officer4.7yrsUS$674.28k0.093%
€ 363.0k
Richard Chen
Executive VP of R&D and Chief Medical Officer3.4yrsUS$1.28m0.17%
€ 655.2k
Russ Altman
Co-Founder and Member of Clinical & Scientific Advisory Boardno datano datano data
Euan Ashley
Co-Founder and Member of Clinical & Scientific Advisory Boardno datano datano data
Michael Snyder
Co-Founder and Member of Clinical & Scientific Advisory Boardno datano datano data
Michael Fitzpatrick
Vice President of Worldwide Sales11.7yrsno datano data
Christian Haudenschild
Senior Vice President of Genomic Laboratory Operations3.3yrsno datano data
Stephane Mouradian
Senior Vice President of Business Development1.9yrsno datano data
Deepshikha Bhandari
Senior Vice President of Regulatory1.2yrsno datano data

3.3yrs

Average Tenure

53yo

Average Age

Experienced Management: 04X's management team is considered experienced (3.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Christopher Hall
President1.8yrsUS$1.73m0.25%
€ 981.5k
Russ Altman
Co-Founder and Member of Clinical & Scientific Advisory Boardno datano datano data
Euan Ashley
Co-Founder and Member of Clinical & Scientific Advisory Boardno datano datano data
Michael Snyder
Co-Founder and Member of Clinical & Scientific Advisory Boardno datano datano data
Kenneth Widder
Independent Director1.5yrsUS$154.00kno data
Karin Eastham
Independent Chair of the Board5.3yrsUS$173.05k0.019%
€ 74.4k
Arthur Bowman
Independent Director5.6yrsUS$121.38k0.019%
€ 74.4k
Woodrow Myers
Independent Director3.8yrsUS$108.88k0.037%
€ 143.9k
John West
Advisor to the Board2yrsUS$5.62mno data
Lonnie Shoff
Independent Director2.3yrsUS$103.88k0.015%
€ 56.8k
Olivia Bloom
Independent Director2.8yrsUS$116.38k0.025%
€ 97.0k

2.5yrs

Average Tenure

67yo

Average Age

Experienced Board: 04X's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 07:31
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Personalis, Inc. is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Derik de BruinBofA Global Research
Mark MassaroBTIG
Patrick DonnellyCitigroup Inc